Why Cassava Sciences Stock Dived by Almost 11% Today
Cassava Sciences (NASDAQ: SAVA) ended the week with a piece of dispiriting news. It's going to reach deep into its coffers to settle charges brought by the most important financial-markets regulator governing its affairs.
Many investors had enough of the company and sold off its stock to the point where it lost nearly 11% of its value across the Friday trading session. That was a far steeper fall than the 0.2% sag of the S&P 500 index on the day.
A $40 million settlement
Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to settle allegations of negligence-based disclosures. The clinical-stage biotech is to pay $40 million in cash in the settlement, and as part of its terms is neither admitting nor denying the allegations.
The SEC had investigated Cassava's statements about a phase 2b clinical trial of simufilam it had made in 2020. This is an investigational drug aimed at treating Alzheimer's disease. It has since advanced to phase 3 testing.
That payout will put quite a dent in Cassava's finances. The company reiterated a previous forecast that, with the settlement payment, its net cash use in operations should total $80 million to $90 million in the second half of this year. It predicts it will finish calendar 2024 with cash on hand of $117 million to $127 million.
Quickly putting it in the past
Cassava also continued to pledge better oversight of its operations and communications. In its press release, it quoted recently appointed CEO Rick Barry as saying that the company "is pleased to put this matter behind us. We can now focus all of our attention on completion of the ongoing Phase 3 trials of simufilam."
Should you invest $1,000 in Cassava Sciences right now?
Before you buy stock in Cassava Sciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cassava Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $760,130!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of September 23, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Why Cassava Sciences Stock Dived by Almost 11% Today was originally published by The Motley Fool